An open-label, multi-centre, non-randomised phase I dose-escalation study to investigate the safety and tolerability of the study drug given as monotherapy in patients with relapsed/refractory non-hodgkin’s lymphoma (NHL) and relapsed/refractory chronic lymphocytic leukaemia (CLL).
Back to Resource Center